Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PembroPlus: Pembrolizumab + Chemotherapy in Advanced Cancer
NCT02331251Phase 2Terminated
- Sponsor
- Western Regional Medical Center
- Start
- Dec 2014
- Primary completion
- Jan 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in cancer, sarcoma, pancreatic adenocarcinoma (PDAC) and 4 more (6 arms), sponsored by Western Regional Medical Center. Primary endpoints: Recommended Phase 2 Dose at 3 weeks and Complete Response. Started Dec 2014; status: terminated.
02
Drugs
03
Conditions
cancersarcomapancreatic adenocarcinoma (PDAC)small cell lung cancer (SCLC)estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT02331251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02331251.